Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|March 29, 2000
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanomaM R Middleton, P Lorigan, J Owen, et al.
British Journal of Cancer|January 7, 2012
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumoursE Dean, M R Middleton, T Pwint, et al.
BMJ Supportive & Palliative Care|May 3, 2014
Quality of life, support and smoking in advanced lung cancer patients: a qualitative studyC Rowland, S J Danson, R Rowe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2015
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancerJ Bendell, E M O'Reilly, M R Middleton, et al.
Melanoma Research|April 4, 2002
Effect of temozolomide on central nervous system relapse in patients with advanced melanomaM J Paul, Y Summers, A H Calvert, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 24, 2012
Sentinel node status predicts survival in thick melanomas: the Oxford perspectiveM G Rughani, M C Swan, T S Adams, et al.
Ultrasonics|March 30, 2004
High-intensity focused ultrasound for the treatment of liver tumoursJ E Kennedy, F Wu, G R ter Haar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2011
Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1S J Danson, P Johnson, T H Ward, et al.
British Journal of Cancer|July 16, 2009
Societal preference values for advanced melanoma health states in the United Kingdom and AustraliaK M Beusterien, S M Szabo, S Kotapati, et al.
British Journal of Cancer|April 28, 2012
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trialJ Cummings, M Zweifel, N Smith, et al.
Pageof 6